Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.23 -36.5%	$3.03	$1.84 ▼ $5.31	$77.35M	1.63	239,791 shs	13.00 million shs
RIGL Rigel Pharmaceuticals	$19.48 +3.8%	$19.48	$7.48 ▼ $29.82	$348.15M	1.29	210,601 shs	551,164 shs
VNDA Vanda Pharmaceuticals	$4.78 -0.8%	$4.39	$3.81 ▼ $6.37	$281.70M	0.66	613,089 shs	716,308 shs
XOMA XOMA Royalty	$27.49 +0.6%	$25.00	$18.35 ▼ $35.00	$328.97M	0.94	34,162 shs	269,597 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-36.47%	-33.43%	-29.21%	-19.78%	-53.15%
RIGL Rigel Pharmaceuticals	+3.84%	+2.91%	+1.51%	+8.95%	+146.55%
VNDA Vanda Pharmaceuticals	-0.83%	+5.99%	+10.90%	+1.92%	-20.07%
XOMA XOMA Royalty	+0.62%	+14.30%	+9.30%	+35.22%	+21.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	1.5752 of 5 stars	3.8	0.0	0.0	2.4	0.0	0.6
RIGL Rigel Pharmaceuticals	2.7955 of 5 stars	3.2	0.0	0.0	1.6	1.7	3.1
VNDA Vanda Pharmaceuticals	4.5613 of 5 stars	3.8	2.0	4.2	2.0	3.3	1.3
XOMA XOMA Royalty	4.396 of 5 stars	3.5	4.0	3.0	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	542.75% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	86.86% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	245.19% Upside
XOMA XOMA Royalty	3.00	Buy	$69.50	152.82% Upside

Current Analyst Ratings Breakdown

Latest ACHV, RIGL, XOMA, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00
5/14/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$13.00
5/13/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/7/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/17/2025	XOMA XOMA Royalty	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
4/1/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00 ➝ $104.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.61 per share	N/A
RIGL Rigel Pharmaceuticals	$179.28M	1.94	$1.08 per share	18.06	$0.19 per share	102.53
VNDA Vanda Pharmaceuticals	$198.77M	1.42	N/A	N/A	$9.24 per share	0.52
XOMA XOMA Royalty	$28.49M	11.55	N/A	N/A	$6.95 per share	3.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.34	N/A	N/A	N/A	N/A	-176.11%	-103.32%	8/12/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$2.07	9.41	18.55	N/A	18.31%	-655.26%	24.47%	8/5/2025 (Estimated)
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.75	N/A	N/A	N/A	-21.98%	-8.30%	-6.85%	7/30/2025 (Estimated)
XOMA XOMA Royalty	-$13.82M	-$1.15	N/A	N/A	N/A	-13.04%	-12.43%	-4.85%	8/12/2025 (Estimated)

Latest ACHV, RIGL, XOMA, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
5/13/2025	Q1 2025	XOMA XOMA Royalty	-$0.26	$0.06	+$0.32	$0.06	$6.75 million	$15.91 million
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.85	3.51	3.51
RIGL Rigel Pharmaceuticals	2.42	2.20	2.13
VNDA Vanda Pharmaceuticals	N/A	3.93	3.91
XOMA XOMA Royalty	1.18	5.54	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
RIGL Rigel Pharmaceuticals	66.23%
VNDA Vanda Pharmaceuticals	88.14%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
RIGL Rigel Pharmaceuticals	9.48%
VNDA Vanda Pharmaceuticals	10.00%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.64 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.18 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.04 million	Optionable
XOMA XOMA Royalty	10	11.97 million	10.88 million	Optionable

ACHV, RIGL, XOMA, and VNDA Headlines

Recent News About These Companies

XOMA Royalty (NASDAQ:XOMA) Downgraded by Wall Street Zen to Hold

June 28 at 3:15 AM | marketbeat.com

XOMA Royalty to Buy Turnstone Biologics

June 27 at 4:23 PM | marketwatch.com

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...

June 27 at 8:54 AM | gurufocus.com

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...

June 27 at 8:54 AM | gurufocus.com

XOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger Deal

June 27 at 8:28 AM | quiverquant.comQ

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27 at 7:30 AM | globenewswire.com

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

June 24, 2025 | zacks.com

XOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average - Should You Sell?

June 24, 2025 | marketbeat.com

XOMA Preferred Shares Series A declares $0.539 dividend

June 18, 2025 | seekingalpha.com

XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend

June 18, 2025 | seekingalpha.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025 | investing.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025 | globenewswire.com

XOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street Zen

June 14, 2025 | marketbeat.com

XOMA (NASDAQ:XOMA) Stock Rating Upgraded by Wall Street Zen

June 1, 2025 | marketbeat.com

HC Wainwright Issues Positive Outlook for XOMA Earnings

May 31, 2025 | marketbeat.com

Positive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy Rating

May 29, 2025 | tipranks.com

XOMA's (XOMA) "Buy" Rating Reaffirmed at HC Wainwright

May 29, 2025 | marketbeat.com

XOMA boosts stake in anti-CD38 antibody with $30 million deal

May 28, 2025 | thepharmaletter.comT

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 28, 2025 | benzinga.com

XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating

May 28, 2025 | tipranks.com

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, RIGL, XOMA, and VNDA Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.23 -1.28 (-36.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.33 +0.10 (+4.53%)

As of 06/27/2025 08:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Rigel Pharmaceuticals NASDAQ:RIGL

$19.48 +0.72 (+3.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$19.52 +0.04 (+0.21%)

As of 06/27/2025 05:08 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.78 -0.04 (-0.83%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.73 -0.05 (-1.07%)

As of 06/27/2025 07:52 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

XOMA Royalty NASDAQ:XOMA

$27.49 +0.17 (+0.62%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$27.46 -0.02 (-0.09%)

As of 06/27/2025 04:34 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time